The market access of an out-patient medicinal product requires in practice that a product is reimbursable through health insurance. The processes of price and reimbursement applications have a growing significance for the success of a pharmaceutical company. In an optimal situation, a new medicinal product is available for patients who need it, in as fast and extensive manner as possible, and at a competitive price.
The basic reimbursement status can be applied directly after receiving the marketing authorization and the special reimbursement status can be applied once the basic reimbursement status has been granted for the medicinal product. The special reimbursement status can be granted, however, only provided that the disease is listed in the Government Decree and that there is sufficient use experience concerning the product. The reimbursement status and the reasonable wholesale price as the basis for the reimbursement must be renewed at regular intervals. Conditional reimbursement has provided a new opportunity for the faster implementation of new innovative medicinal products reimbursed through health insurance.
A successful application process requires high-quality documentation of the therapeutic and economic value of the product, knowledge of the Health Insurance Act and a tactic eye in different phases of the application process.
Sr. Market Access Manager
Ritva joined Medaffcon’s Market Access team in March 2018. Before this, she worked almost six years at Farenta in corresponding tasks, providing pharmaceutical companies with strategic consultation and expert assistance related to Market Access functions. In addition, Ritva holds more than 20 years of experience in the pharmaceutical industry, where she has worked as a Market Access Manager at Sanofi (12 years), as a Regulatory Affairs Manager at Bayer and as a Researcher in Pharmaceutical Product Development at Orion.
In the pharmaceutical industry, Ritva is interested in Market Access issues particularly due to their diversity and societal impact. “Market Access is a great lookout spot to observe the development of new innovative medicinal treatment, aiming to improve patients’ treatment in its entirety. I consider it important to increase cooperation between different actors in the pharmaceutical industry and to find such new solution models that make effective treatment optimally available for patients without raising the society’s costs unreasonably. “
Ritva holds extensive and diverse experience and expertise in pricing and reimbursement issues of primary care medicine and hospital medicine in several different therapeutic areas. Over the years, Ritva has also trained and guided many colleagues in Market Access tasks. In project work, Ritva deems it important to be customer-oriented, and satisfied customers have always been the best reward for a job well done. Ritva is active, analytic and a creative seeker for solutions with good team working abilities.
Jarmo joined Medaffcon as a Partner and Managing Director in 2010, after previously working in different positions in the pharmaceutical industry for eight years. Jarmo holds a comprehensive understanding of the pharmaceutical field: he has worked in several expert and leading positions, e.g. as a Health Economic Expert, Head of a Pricing and Reimbursement Unit and as a Director of Health Economics and Market Access teams. Before moving to the pharmaceutical industry, Jarmo had a permanent position in Turku School of Economics and he worked as a researcher at Turku University Hospital.
Due to his background, Jarmo has a strong knowledge of how new health technological innovations can meet the requirements and expectations of authorities, markets and customers. Medaffcon also benefits from his comprehensive experience in Health Economics and its applications from the perspective of research and commercialisation. In addition, he has wide-ranging understanding of the constantly changing operational environment.
Jarmo deems Market Access as multidisciplinary and crucial to business, which makes it an extremely interesting field of operation.
Jr. Health Economist
Heini joined Medaffcon’s Market Access team in May 2018. Heini is finishing her studies in Health Economics at the University of Eastern Finland, and her master’s thesis discusses risk-sharing agreements in the pharmaceutical market. Heini’s interest in the connections between health and economy was aroused already during her former health-related University studies and patient work.
Heini is interested in the changes occurring in the pharmaceutical and healthcare industries as well as in the possibilities of Health Economics in assessing the methods and economic resources in the field. Heini’s assets include her state-of-the-art theoretical knowledge in the field of Health Economics, combined with pratice-oriented thinking.
Market Access Specialist
M.Sc. (Pharmacy), M.Sc. (Natural Science)
Joel started working at Medaffcon in December 2015 as a Market Access Specialist. Previously, he has worked for two years in international Market Access tasks (antidepressants and antipsychotics). In addition to this, he has experience in working as a Market Access Consultant and at a pharmacy.
Joel is educated as a Master of Science (Pharmacy) degree, specialised in biopharmaceutics. Moreover, he has a Master of Science (Natural Sciences) degree in applied biotechnology. In the field, Joel is interested in the pricing and reimbursement processes as well as in the related influential parties, which enable the best possible requirements for making the pharmaceutical product available to the patient.
Jr. Health Economist
Lotta joined Medaffcon’s Market Access team in February 2017. Lotta is completing her Master’s studies in Health Economics at the University of Eastern Finland. Just before joining Medaffcon, she returned from an exchange period in Germany. Lotta has experience in the pharmaceutical industry through working at Orion, where she served as a summer employee in the department responsible for supply chain and medicine registration.
Within the pharmaceutical industry, Lotta finds its diversity and international operating environment interesting. In Health Economics, her special interests cover the utilisation of health economic information in the decision-making of the pharmaceutical industry and healthcare, as well as the application of Economics with a health economic perspective. Lotta’s strengths include her interest and curiosity to learn how the theory basis gained through studies in Health Economics can be applied in practical work.
M.Sc. (Health Economics)
Triin joined Medaffcon’s health economic team in April 2015. Triin has a Master of Science degree in Health Care, major in Health Economics, and is a Registered Nurse. Triin has gained work experience in the pharmaceutical industry at Janssen-Cilag Oy in Health Economic and Market Access tasks, including pricing and reimbursement applications, reference price system and hospital tenders. She has also worked as a Market Access Trainee at Pfizer. Triin has experience also in the public sector, both as a registered nurse and in the public procurement tendering and acquisition processes at Kela.
Triin is interested in the diversified utilisation of the information produced by health economics and moving it to the level of practice, in particular promoting the adoption of cost-effective healthcare measures. Triin’s strengths include both theoretical knowledge and practical experience in private and public sectors as well as in a hospital environment. In her work, Triin enjoys developing solutions for challenging questions.